The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

Research for the Development of an Integrated Medical System for Idiopathic Pulmonary Fibrosis: Based on an Analysis of Questionnaire Survey in Doctor and Patient Groups

특발성 폐섬유증의 통합의료 협진 모델 개발을 위한 의료진 및 환자 대상 설문조사 연구

  • Jiwon Park (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University) ;
  • Beom-Joon Lee (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University) ;
  • Jeong-Won Shin (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University) ;
  • Su-Hyun Chin (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University) ;
  • Jung-Min Yang (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University) ;
  • Sooduk Kim (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University) ;
  • Kwan-Il Kim (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University) ;
  • Hye Sook Choi (Dept. of Internal Medicine, Kyung Hee University Medical Center) ;
  • Hee-Jae Jung (Division of Allergy, Immune & Respiratory System, Dept. of Internal Medicine, Graduate School, Kyung Hee University)
  • 박지원 (경희대학교 대학원 임상한의학과 폐계내과학교실) ;
  • 이범준 (경희대학교 대학원 임상한의학과 폐계내과학교실) ;
  • 신정원 (경희대학교 대학원 임상한의학과 폐계내과학교실) ;
  • 진수현 (경희대학교 대학원 임상한의학과 폐계내과학교실) ;
  • 양정민 (경희대학교 대학원 임상한의학과 폐계내과학교실) ;
  • 김수덕 (경희대학교 대학원 임상한의학과 폐계내과학교실) ;
  • 김관일 (경희대학교 대학원 임상한의학과 폐계내과학교실) ;
  • 최혜숙 (경희의료원 내과) ;
  • 정희재 (경희대학교 대학원 임상한의학과 폐계내과학교실)
  • Received : 2023.05.12
  • Accepted : 2023.06.20
  • Published : 2023.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: In this study, a questionnaire survey was conducted for doctors and patients to obtain basic data necessary for the development of an integrated medical system for idiopathic pulmonary fibrosis (IPF). Methods: Questionnaires were developed separately for doctors and patients through an expert group meeting. The survey subjects were recruited online and offline, and finally, responses from 231 doctors and 59 patients were used for statistical analysis. Results: The most important parts in the treatment of IPF for both doctors and patients were the "improvement of respiratory symptoms," "improvement of quality of life," and "prevention of disease progression." Antifibrotic agents were prescribed at a high rate, and 100% of the specialists in Western medicine (WM) and 45.8% of patients reported experiencing side effects. As for the additional payment costs that patients considered as affordable for an integrated medical system, "under 50,000 won (about 38$)" was reported the most in both doctor and patient groups. With regard to the reasons for their reluctance to recommend an integrated medical system for IPF, specialists in WM responded highly to "uncertain evidence for treatment effectiveness." Regarding complementary and alternative medicine therapies that can be beneficial in patients with IPF, "lifestyle management," "diet management," "herb," "relaxation therapy," and "psychotherapy" were ranked high in both doctor and patient groups. Conclusions: In this study, a questionnaire survey on IPF was conducted to review actual treatment status, analyze shortcomings, and identify considerations for the development of an integrated medical system for IPF in the future.

Keywords

Acknowledgement

본 연구는 보건복지부의 재원으로 한국보건산업진흥원의 통합의료연구지원사업과 한의기반융합기술개발사업 지원에 의하여 이루어진 것임(과제번호: HI20C1405, HI20C1205).

References

  1. King Jr TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. The Lancet 2011;378(9807):1949-61. https://doi.org/10.1016/S0140-6736(11)60052-4
  2. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. The Lancet 2017;389(10082):1941-52. https://doi.org/10.1016/S0140-6736(17)30866-8
  3. Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. European Respiratory Journal 2015;46(4):1113-30. https://doi.org/10.1183/13993003.02316-2014
  4. Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE. Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review. European Respiratory Review 2020;29(157):190158.
  5. Kim SW, Myong JP, Yoon HK, Koo JW, Kwon SS, Kim YH. Health care burden and medical resource utilisation of idiopathic pulmonary fibrosis in Korea. Int J Tuberc Lung Dis 2017;21(2):230-5. https://doi.org/10.5588/ijtld.16.0402
  6. Zaman T, Lee JS. Risk factors for the development of idiopathic pulmonary fibrosis: A review. Curr Pulmonol Rep 2018;7(4):118-25. https://doi.org/10.1007/s13665-018-0210-7
  7. Cox IA, Borchers Arriagada N, de Graaff B, Corte TJ, Glaspole I, Lartey S, et al. Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. European Respiratory Review 2020;29(158):200154.
  8. Gao J, Kalafatis D, Carlson L, Pesonen IH, Li CX, Wheelock A, et al. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respiratory research 2021;22(1):40.
  9. Noble PW, Albera C, Bradford WZ, Costabel U, Du Bois RM, Fagan EA, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. European Respiratory Journal 2016;47(1):243-53. https://doi.org/10.1183/13993003.00026-2015
  10. Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respiratory Research 2019;6(1):e000397.
  11. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respiratory research 2017;18(1):139.
  12. Kim ES, Keating GM. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. Drugs 2015;75(2):219-30. https://doi.org/10.1007/s40265-015-0350-9
  13. Margaritopoulos GA, Trachalaki A, Wells AU, Vasarmidi E, Bibaki E, Papastratigakis G, et al. Pirfenidone improves survival in IPF: results from a real-life study. BMC pulmonary medicine 2018;18(1):177.
  14. Cohen MH. Complementary and integrative medical therapies, the FDA, and the NIH: definitions and regulation. Dermatologic therapy 2003;16(2):77-84. https://doi.org/10.1046/j.1529-8019.2003.01614.x
  15. Ji K, Ma J, Wang L, Li N, Dong S, Shi L. Efficacy and safety of traditional Chinese medicine in idiopathic pulmonary fibrosis: a meta-analysis. Evidence-Based Complementary and Alternative Medicine 2020;2020:1752387.
  16. Kalnins P, Brucker M, Spears D. Prolonged Survival in a Patient with Idiopathic Pulmonary Fibrosis Receiving Acupuncture and DHEA-Promoting Herbs with Conventional Management: A Case Report. The Permanente Journal 2019;23:18-074. https://doi.org/10.7812/TPP/18-074
  17. Li B, Zhang Y, Yang QM. Umbilical moxibustion for patients with idiopathic pulmonary fibrosis complicated with gastroesophageal reflux of lung-spleen qi deficiency. Chinese Acupuncture & Moxibustion 2019;39(3):241-5.
  18. Yu X, Li X, Wang L, Liu R, Xie Y, Li S, et al. Pulmonary rehabilitation for exercise tolerance and quality of life in IPF patients: a systematic review and meta-analysis. BioMed research international 2019;2019:8498603.
  19. Guler SA, Lindell KO, Swigris J, Ryerson CJ. Nondrug Treatments for Idiopathic Pulmonary Fibrosis: IPF Part 3. American journal of respiratory and critical care medicine 2021;203(4):P10-P11. https://doi.org/10.1164/rccm.2034P10
  20. Mercader-Barcelo J, Truyols-Vives J, Rio C, Lopez-Safont N, Sala-Llinas E, Chaplin A. Insights into the role of bioactive food ingredients and the microbiome in idiopathic pulmonary fibrosis. International Journal of Molecular Sciences 2020;21(17):6051.
  21. Duck A, Pigram L, Errhalt P, Ahmed D, Chaudhuri N. IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe. Advances in therapy 2015;32(2):87-107. https://doi.org/10.1007/s12325-015-0183-7
  22. Lee HY, Lee DH, Lee GE, Kim JH, Kim HM, Kim NK. Survey on the satisfaction and demand of healthcare providers who participated in a collaborative first-stage pilot project between Korean medicine and western medicine. Journal of physiology & pathology in Korean Medicine 2018;32(2):134-40. https://doi.org/10.15188/kjopp.2018.04.32.2.134
  23. Li M, Wu R, Zhao Y, Li L, Li G, Liu S, et al. Chinese Herbal Medicine for Idiopathic Pulmonary Fibrosis: An Overview of Systematic Review. Alternative Therapies in Health and Medicine 2023:AT8195.
  24. Kim Y, Lee Y, Yoon S, Huh J. Nutritional factors affecting the mortality in patients with chronic lung disease. Current Developments in Nutrition 2020;4(Supplement_2):41.
  25. Volpato E, Banfi P, Rogers SM, Pagnini F. Relaxation techniques for people with chronic obstructive pulmonary disease: a systematic review and a meta-analysis. Evidence-Based Complementary and Alternative Medicine 2015;2015:628365.
  26. Choi WI. Current and future treatment for idiopathic pulmonary fibrosis. Journal of the Korean Medical Association 2021;64(4):256-63. https://doi.org/10.5124/jkma.2021.64.4.256
  27. Shimizu Y, Shimoyama Y, Kawada A, Kusano M, Hosomi Y, Sekiguchi M, et al. Gastrointestinal symptoms in idiopathic pulmonary fibrosis patients treated with pirfenidone and herbal medicine. Journal of Biological Regulators and Homeostatic Agents 2014;28(3):433-42.
  28. Park JE, Kwon SM. Determinants of the utilization of oriental medical services by the elderly. The Journal of Korean Medicine 2011;32(1):97-108.
  29. Vainshelboim B, Oliveira J, Izhakian S, Unterman A, Kramer MR. Lifestyle Behaviors and Clinical Outcomes in Idiopathic Pulmonary Fibrosis. Respiration 2018;95(1):27-34. https://doi.org/10.1159/000481202
  30. Poswal FS, Russell G, Mackonochie M, MacLennan E, Adukwu EC, Rolfe V. Herbal teas and their health benefits: a scoping review. Plant Foods for Human Nutrition 2019;74(3):266-76. https://doi.org/10.1007/s11130-019-00750-w
  31. Van Manen M, Kreuter M, Van Den Blink B, Oltmanns U, Baroke E, Palmowski K, et al. What patients with pulmonary fibrosis and their partners really think; live patient and partner survey on pulmonary fibrosis in the netherlands and germany. A41. Here there and everywhere: ILD observational studies: American Thoracic Society 2015;191:A1591.